Related Experiment Videos
Pathologic staging of prostate carcinoma. What are the issues?
1Department of Pathology, Harper Hospital, Wayne State University, Detroit, MI 48201, USA.
Cancer
|July 15, 1996
Summary
A standardized pathologic staging system for prostate cancer is needed to complement the current clinical TNM system. Key issues include T2 tumor subcategorization, extraprostatic extension, and surgical margin reporting for better patient outcome prediction.
Area of Science:
- Urology
- Oncology
- Pathology
Background:
- Prostate carcinoma staging is crucial for predicting patient outcomes.
- The American Joint Committee on Cancer (AJCC) and International Union Against Cancer (UICC) TNM system is the preferred clinical staging method.
- A uniform pathologic staging system is required to support clinical staging and prognostic assessment.
Purpose of the Study:
- To review literature on pathologic prognostic markers for prostate carcinoma.
- To identify key issues for developing a pathologic staging system.
- To establish a pathologic correlate to the AJCC/UICC TNM system.
Main Methods:
- Literature review focused on pathologic prognostic markers and staging in prostate carcinoma.
- Identification of critical elements for a pathologic staging system.
Main Results:
- Several issues emerged regarding the development of a pathologic staging system for prostate cancer.
- Important considerations for radical prostatectomy specimens include T2 tumor subcategorization, defining extraprostatic extension, and reporting positive surgical margins.
Conclusions:
- A pathologic staging system equivalent to the AJCC/UICC TNM clinical system is necessary for prostate carcinoma.
- Consensus on critical issues is required before adopting and validating such a system.